BC Week In Review | Jan 5, 2009
Company News

AlphaVax, Novartis deal

AlphaVax granted Novartis exclusive, worldwide rights to develop and commercialize CMV alphavaccine ( AVX601 ) to prevent cytomegalovirus (CMV) infection. AlphaVax will receive $20 million up front and is eligible for undisclosed milestones and royalties. AlphaVax is...
BC Week In Review | Apr 21, 2008
Clinical News

CMV alphavaccine: Phase I data

Initial data from a double-blind, placebo-controlled, U.S. Phase I trial (AVX601-001) in 40 healthy volunteers showed that AVX601 was safe and well tolerated. Most volunteers developed antibody or T cell responses to all 3 CMV...
BC Week In Review | Apr 16, 2007
Clinical News

CMV alphavaccine: Phase I started

AlphaVax started a double-blind, placebo-controlled Phase I trial in 40 healthy volunteers. AlphaVax Inc. , Research Park Triangle, N.C.   Product: CMV alphavaccine ( AVX601 )   Business: Infectious   Molecular target: NA   Description: Vaccine containing three...
BC Week In Review | Feb 5, 2007
Clinical News

CMV alphavaccine: Phase I start

This month, AlphaVax will begin a Phase I trial in 40 healthy volunteers. AlphaVax Inc. , Research Park Triangle, N.C.   Product: CMV alphavaccine   Business: Infectious   Molecular target: NA   Description: Vaccine containing three...
Items per page:
1 - 4 of 4